Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
3320.HK
Top 10 Correlated ETFs
3320.HK
Top 10 Correlated Stocks
3320.HK
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 27.45 | 30.18 | 32.53 | 31.9 | 37.69 | |
| Net income per share | 0.55 | 0.64 | 0.52 | 0.52 | 0.6 | |
| Operating cash flow per share | 0.77 | 1.31 | 1.3 | 1.31 | 2.04 | |
| Free cash flow per share | 0.45 | 1 | 0.97 | 0.95 | 1.54 | |
| Cash per share | 3.3 | 7.11 | 6.19 | 7.3 | 9.19 | |
| Book value per share | 6.66 | 6.27 | 6.48 | 7.4 | 8.11 | |
| Tangible book value per share | 5.59 | 5.27 | 7.02 | 8.27 | 9.72 | |
| Share holders equity per share | 6.66 | 6.27 | 6.48 | 7.4 | 8.11 | |
| Interest debt per share | 6.22 | 8.57 | 7.16 | 7.53 | 9.44 | |
| Market cap | 65.23B | 68.88B | 42.48B | 25.64B | 23.25B | |
| Enterprise value | 87.95B | 103.18B | 71.22B | 58.56B | 62.28B | |
| P/E ratio | 18.73 | 17.06 | 12.93 | 7.77 | 6.17 | |
| Price to sales ratio | 0.38 | 0.36 | 0.21 | 0.13 | 0.1 | |
| POCF ratio | 13.43 | 8.35 | 5.22 | 3.12 | 1.81 | |
| PFCF ratio | 22.86 | 10.99 | 6.96 | 4.28 | 2.4 | |
| P/B Ratio | 1.56 | 1.75 | 1.04 | 0.55 | 0.46 | |
| PTB ratio | 1.56 | 1.75 | 1.04 | 0.55 | 0.46 | |
| EV to sales | 0.51 | 0.54 | 0.35 | 0.29 | 0.26 | |
| Enterprise value over EBITDA | 9.78 | 10.13 | 6.53 | 5.5 | 5.61 | |
| EV to operating cash flow | 18.11 | 12.51 | 8.75 | 7.14 | 4.85 | |
| EV to free cash flow | 30.81 | 16.46 | 11.68 | 9.78 | 6.42 | |
| Earnings yield | 0.05 | 0.06 | 0.08 | 0.13 | 0.16 | |
| Free cash flow yield | 0.04 | 0.09 | 0.14 | 0.23 | 0.42 | |
| Debt to equity | 0.08 | 0.26 | 0.27 | 0.07 | 0.16 | |
| Debt to assets | 0.61 | 0.66 | 0.63 | 0.62 | 0.62 | |
| Net debt to EBITDA | 2.53 | 3.37 | 2.64 | 3.09 | 3.52 | |
| Current ratio | 1.23 | 1.24 | 1.25 | 1.2 | 1.25 | |
| Interest coverage | 4.55 | 4.04 | 2.59 | 3.59 | 4.44 | |
| Income quality | 1.39 | 2.04 | 2.48 | 2.49 | 3.41 | |
| Dividend Yield | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | |
| Payout ratio | 0.16 | 0.17 | 0.25 | 0.21 | 0.2 | |
| Sales general and administrative to revenue | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.17 | 0.16 | 0.13 | 0.13 | 0.14 | |
| Capex to operating cash flow | -0.41 | 0 | -0.25 | -0.27 | -0.24 | |
| Capex to revenue | -0.01 | 0 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -1.28 | -0.01 | -0.86 | -0.91 | -1.11 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 9.11 | 9.52 | 8.73 | 9.34 | 10.47 | |
| ROIC | 0.15 | 0.16 | 0.12 | 0.13 | 0.11 | |
| Return on tangible assets | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Graham Net | -10.53 | -9.59 | -11.19 | -11.33 | -12.89 | |
| Working capital | 21.46B | 25B | 26.27B | 24.49B | 35.29B | |
| Tangible asset value | 35.15B | 33.14B | 44.12B | 51.99B | 61.08B | |
| Net current asset value | 15.58B | 12.64B | 12.5B | 17.77B | 23.03B | |
| Invested capital | 0.88 | 1.29 | 1.01 | 0.95 | 1.11 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 43.94B | 42.6B | 44.21B | 45.7B | 48.98B | |
| Average inventory | 23B | 23.06B | 23.46B | 24.58B | 27.14B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 106.75 | 93.18 | 91.51 | 99.21 | 94.72 | |
| Days of inventory on hand | 54.16 | 50.77 | 47.83 | 53.37 | 53.8 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 3.42 | 3.92 | 3.99 | 3.68 | 3.85 | |
| Inventory turnover | 6.74 | 7.19 | 7.63 | 6.84 | 6.78 | |
| ROE | 0.08 | 0.1 | 0.08 | 0.07 | 0.07 | |
| Capex per share | -0.32 | 0 | -0.32 | -0.35 | -0.5 |
Quarterly Fundamentals Overview
Last date of statement is 2019-06-30 for Q2
| Metric | History | 2017-06-30 | 2018-06-30 | 2019-06-30 |
|---|---|---|---|---|
| Revenue per share | 6.86 | 7.55 | 8.13 | |
| Net income per share | 0.14 | 0.16 | 0.13 | |
| Operating cash flow per share | 0.19 | 0.33 | 0.32 | |
| Free cash flow per share | 0.11 | 0.25 | 0.24 | |
| Cash per share | 3.1 | 4.39 | 6.97 | |
| Book value per share | 6.35 | 6.67 | 6.57 | |
| Tangible book value per share | 5.21 | 5.57 | 6.74 | |
| Share holders equity per share | 6.35 | 6.67 | 6.57 | |
| Interest debt per share | 5.84 | 7.33 | 10 | |
| Market cap | 61.27B | 68.25B | 56.81B | |
| Enterprise value | 80.92B | 102.31B | 103.88B | |
| P/E ratio | 17.59 | 16.9 | 17.29 | |
| Price to sales ratio | 1.42 | 1.44 | 1.11 | |
| POCF ratio | 50.46 | 33.1 | 27.91 | |
| PFCF ratio | 85.88 | 43.55 | 37.25 | |
| P/B Ratio | 1.54 | 1.63 | 1.38 | |
| PTB ratio | 1.54 | 1.63 | 1.38 | |
| EV to sales | 1.88 | 2.16 | 2.03 | |
| Enterprise value over EBITDA | 35.98 | 40.17 | 38.1 | |
| EV to operating cash flow | 66.64 | 49.62 | 51.04 | |
| EV to free cash flow | 113.41 | 65.28 | 68.11 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0.02 | 0.03 | |
| Debt to equity | 0.09 | 0.12 | 0.31 | |
| Debt to assets | 0.77 | 0.63 | 0.65 | |
| Net debt to EBITDA | 8.74 | 13.37 | 17.26 | |
| Current ratio | 2.47 | 1.23 | 1.24 | |
| Interest coverage | 4.55 | 4.04 | 2.59 | |
| Income quality | 1.39 | 2.04 | 2.48 | |
| Dividend Yield | 0 | 0 | 0 | |
| Payout ratio | 0.16 | 0.17 | 0.25 | |
| Sales general and administrative to revenue | 0.02 | 0.03 | 0.03 | |
| Research and developement to revenue | 0 | 0 | 0 | |
| Intangibles to total assets | 0.1 | 0.17 | 0.13 | |
| Capex to operating cash flow | -0.41 | 0 | -0.25 | |
| Capex to revenue | -0.01 | 0 | -0.01 | |
| Capex to depreciation | -1.28 | -0.01 | -0.86 | |
| Stock based compensation to revenue | 0 | 0 | 0 | |
| Graham number | 4.45 | 4.91 | 4.4 | |
| ROIC | 0.01 | 0.04 | 0.03 | |
| Return on tangible assets | 0 | 0.01 | 0 | |
| Graham Net | -27.09 | -10.6 | -11.95 | |
| Working capital | 127.82B | 22.79B | 27.78B | |
| Tangible asset value | 32.75B | 35B | 42.36B | |
| Net current asset value | 14.55B | 15.28B | 12.15B | |
| Invested capital | 0.91 | 1.08 | 1.5 | |
| Average receivables | 0 | 0 | 0 | |
| Average payables | 51.8B | 46.48B | 47.46B | |
| Average inventory | 25.23B | 26.2B | 26.21B | |
| Days sales outstanding | 0 | 0 | 0 | |
| Days payables outstanding | 128.07 | 94.65 | 90.1 | |
| Days of inventory on hand | 51.86 | 52.81 | 48.01 | |
| Receivables turnover | 0 | 0 | 0 | |
| Payables turnover | 0.7 | 0.95 | 1 | |
| Inventory turnover | 1.74 | 1.7 | 1.87 | |
| ROE | 0.02 | 0.02 | 0.02 | |
| Capex per share | -0.08 | 0 | -0.08 |
Frequently Asked Questions
What is China Resources Pharmaceutical Group Limited stock symbol ?
China Resources Pharmaceutical Group Limited is a HK stock and trading under the symbol 3320.HK
What is China Resources Pharmaceutical Group Limited stock quote today ?
China Resources Pharmaceutical Group Limited stock price is $6.22 today.
Is China Resources Pharmaceutical Group Limited stock public?
Yes, China Resources Pharmaceutical Group Limited is a publicly traded company.
Company Profile
- Volume Average 14.22M
- Market Capitalization 38.95B
- Employee 62K
- CEO Mr. Yuewei Han
- Headquarters HK
- IPO Date 2016-10-28
-
Website
https://www.crpharm.com 
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
